Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

Sorafenib, a multi-tyrosine kinase inhibitor, kills more effectively the non-metastatic prostate cancer cell line 22Rv1 than the highly metastatic prostate cancer cell line PC3. In 22Rv1 cells, constitutively active STAT3 and ERK are targeted by sorafenib, contrasting with PC3 cells, in which these...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharaziha, P, Rodriguez, P, Li, Q, Rundqvist, H, Björklund, A-C, Augsten, M, Ullén, A, Egevad, L, Wiklund, P, Nilsson, S, Kroemer, G, Grander, D, Panaretakis, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270278/
https://www.ncbi.nlm.nih.gov/pubmed/22278289
http://dx.doi.org/10.1038/cddis.2012.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270278/
https://www.ncbi.nlm.nih.gov/pubmed/22278289
http://dx.doi.org/10.1038/cddis.2012.1

Ejemplares similares